Oramed (ORMP) to Conduct Sub-Study on Oral Insulin per FDA Request
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kitov Pharma (KTOV) Announces New Data From Phase III Study of KIT-302
- Nve Corp (VEC) Comments on Thule decision
- Teva Pharma (TEVA) Receives Positive CHMP Opinion on CINQAERO
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!